Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0XPNCZ
ADC Name	SGN-CD70A
Synonyms	SGNCD-70A; SGN-70A; SGN CD70A; SGN 70A; SGNCD70A Click to Show/Hide
Organization	Seagen Inc.
Drug Status	Terminated in phase 2
Indication	In total 6 Indication(s) Renal cell carcinoma [ICD11:2C90] Terminated in phase 2 Diffuse large B-cell lymphoma [ICD11:2A81] Terminated in phase 1 Follicular lymphoma [ICD11:2A80] Terminated in phase 1 Kidney cancer [ICD11:2C90-2C91] Terminated in phase 1 Mantle cell lymphoma [ICD11:2A85] Terminated in phase 1 Non Hodgkin lymphoma [ICD11:2B33] Terminated in phase 1
Drug-to-Antibody Ratio	2
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	CD70 antigen (CD70)		Antigen Info
Payload Name	PBD dimer		Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)		Target Info
Linker Name	Undisclosed
Puchem SID	402425718 , 440234891 , 472419974
DrugMap ID	DMMJ1PO
TTD ID	D0E2ZX
ChEBI ID	CHEMBL4594498

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT02216890	Phase 1	Safety study of SGN-CD70A in cancer patients.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	20.00%	Positive CD70 expression (CD70+++/++)
Patients Enrolled	CD70-positive MCL or DLBCL including FL3b (expression in at least 50% of the sample)
Administration Dosage	8 mg/kg (up to a maximum of 200 mg) intravenously once every 3 weeks.
*Related Clinical Trial*
NCT Number	NCT02216890	Clinical Status	Phase 1
Clinical Description	Safety study of SGN-CD70A in cancer patients.
Primary Endpoint	Objective response rate=20.00% (95% CI 5.70-43.70).
Other Endpoint	Median progression free survival=1.90 months.

References

Ref 1	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest New Drugs. 2019 Apr;37(2):297-306. doi: 10.1007/s10637-018-0655-0. Epub 2018 Aug 22.